WHITTIER TRUST CO - CYTOMX THERAPEUTICS INC ownership

CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 68 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.30 and the average weighting 0.0%.

Quarter-by-quarter ownership
WHITTIER TRUST CO ownership history of CYTOMX THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$2,684
-81.4%
2,200
-66.7%
0.00%
Q1 2024$14,396
+41.6%
6,6040.0%0.00%
Q4 2023$10,170
+20.3%
6,6040.0%0.00%
Q3 2023$8,453
-41.2%
6,604
-21.0%
0.00%
Q2 2023$14,383
+14.7%
8,3630.0%0.00%
Q1 2023$12,544
-5.7%
8,3630.0%0.00%
Q4 2022$13,296
+10.8%
8,3630.0%0.00%
Q3 2022$12,000
-20.0%
8,3630.0%0.00%
Q2 2022$15,000
-48.3%
8,363
-24.0%
0.00%
Q1 2022$29,000
-39.6%
11,0080.0%0.00%
-100.0%
Q4 2021$48,000
-14.3%
11,0080.0%0.00%0.0%
Q3 2021$56,000
-20.0%
11,0080.0%0.00%0.0%
Q2 2021$70,000
-17.6%
11,0080.0%0.00%
-50.0%
Q1 2021$85,000
+18.1%
11,0080.0%0.00%0.0%
Q4 2020$72,000
-1.4%
11,0080.0%0.00%0.0%
Q3 2020$73,000
-20.7%
11,0080.0%0.00%
-33.3%
Q2 2020$92,000
+9.5%
11,0080.0%0.00%0.0%
Q1 2020$84,000
-7.7%
11,0080.0%0.00%
+50.0%
Q4 2019$91,000
+12.3%
11,0080.0%0.00%0.0%
Q3 2019$81,000
-34.7%
11,0080.0%0.00%
-50.0%
Q2 2019$124,000
+5.1%
11,0080.0%0.00%0.0%
Q1 2019$118,000
-28.9%
11,0080.0%0.00%
-33.3%
Q4 2018$166,000
-18.6%
11,0080.0%0.01%0.0%
Q3 2018$204,000
-32.5%
11,008
-16.7%
0.01%
-40.0%
Q2 2018$302,000
-19.7%
13,2130.0%0.01%
-23.1%
Q1 2018$376,00013,2130.01%
Other shareholders
CYTOMX THERAPEUTICS INC shareholders Q2 2023
NameSharesValueWeighting ↓
Canaan Partners IX LLC 4,244,381$43,378,000100.00%
VHCP Management II, LLC 577,831$5,905,0003.56%
REGENTS OF THE UNIVERSITY OF CALIFORNIA 71,366$729,0002.45%
Casdin Capital, LLC 234,179$2,392,0002.38%
BVF INC/IL 606,138$6,192,0001.32%
Opaleye Management Inc. 160,000$1,634,0001.09%
Redmile Group, LLC 733,899$7,497,0000.72%
VHCP Management, LLC 64,200$656,0000.68%
Montecito Bank & Trust 146,544$1,497,0000.63%
Cormorant Asset Management, LP 371,636$3,796,0000.54%
View complete list of CYTOMX THERAPEUTICS INC shareholders